-
CORT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Corcept Therapeutics (CORT)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 127.67 mm | 127.67 mm | 127.67 mm | 127.67 mm | 127.67 mm | 127.67 mm |
Cash burn (monthly) | 3.21 mm | 657.17 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 8.08 mm | 1.66 mm | n/a | n/a | n/a | n/a |
Cash remaining | 119.58 mm | 126.01 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 37.3 | 191.7 | n/a | n/a | n/a | n/a |
13F holders | Current |
---|---|
Total holders | 367 |
Opened positions | 83 |
Closed positions | 37 |
Increased positions | 116 |
Reduced positions | 120 |
13F shares | Current |
---|---|
Total value | 3.76 tn |
Total shares | 84.17 mm |
Total puts | 1.33 mm |
Total calls | 1.04 mm |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 15.68 mm | $789.98 bn |
Vanguard | 10.12 mm | $509.73 bn |
Ingalls & Snyder | 8.10 mm | $408.15 mm |
Renaissance Technologies | 6.20 mm | $312.35 bn |
Parallel Advisors | 3.83 mm | $192.98 bn |
STT State Street | 3.55 mm | $178.80 bn |
Dimensional Fund Advisors | 2.08 mm | $104.74 bn |
Geode Capital Management | 2.07 mm | $104.24 bn |
Arrowstreet Capital, Limited Partnership | 1.64 mm | $82.89 bn |
Jacobs Levy Equity Management | 1.38 mm | $69.38 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 25 | Gary Charles Robb | Common Stock | Gift | Acquire G | Yes | No | 0 | 1,000 | 0.00 | 10,665 |
12 Mar 25 | Gary Charles Robb | Common Stock | Gift | Acquire G | Yes | No | 0 | 1,000 | 0.00 | 10,665 |
12 Mar 25 | Gary Charles Robb | Common Stock | Gift | Dispose G | No | No | 0 | 4,625 | 0.00 | 18,865 |
10 Mar 25 | Daniel N Swisher JR | Common Stock | Sell | Dispose S | No | Yes | 53.6 | 2,200 | 117.92 k | 0 |
10 Mar 25 | Daniel N Swisher JR | Common Stock | Option exercise | Acquire M | No | No | 12.13 | 2,200 | 26.69 k | 2,200 |
10 Mar 25 | Daniel N Swisher JR | Stock option Common Stock | Option exercise | Dispose M | No | No | 12.13 | 2,200 | 26.69 k | 4,000 |
3 Mar 25 | Gary Charles Robb | Common Stock | Grant | Acquire A | No | No | 0 | 292 | 0.00 | 23,490 |
3 Mar 25 | Gary Charles Robb | Common Stock | Grant | Acquire A | No | No | 59.07 | 292 | 17.25 k | 23,198 |
3 Mar 25 | Gary Charles Robb | Common Stock | Payment of exercise | Dispose F | No | No | 60.58 | 250 | 15.15 k | 22,906 |
3 Mar 25 | Mokari Atabak | Common Stock | Grant | Acquire A | No | No | 0 | 232 | 0.00 | 13,034 |